Cargando…

Pharmacokinetic–pharmacodynamic analysis of human purified C1-esterase inhibitor in patients with sepsis

Detalles Bibliográficos
Autores principales:	Dolzhenkova, L, Lazareva, N, Igonin, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088753/ http://dx.doi.org/10.1186/cc6603

Ejemplares similares

Compliment activity patterns in patients with sepsis after human purified C1-esterase inhibitor infusion
por: Igonin, A, et al.
Publicado: (2009)

C1-esterase inhibitor (C1INH) implication in systemic inflammation in sepsis
por: Igonin, A, et al.
Publicado: (2010)

Study of the effect of C1-esterase inhibitor administration to the sepsis pig model
por: Imahase, Hisashi, et al.
Publicado: (2013)

Pharmacokinetic/pharmacodynamic analysis of linezolid in critically ill patients with severe sepsis treated with renal replacement therapy
por: Barrasa González, H, et al.
Publicado: (2015)

Pharmacodynamics and pharmacokinetics of ciprofloxacin during sustained low-efficiency dialysis
por: Olsen, K, et al.
Publicado: (2014)

Effect of C1-esterase inhibitor treatment on microcirculatory perfusion after superior mesenteric artery ischemia
por: Lauterbach, M, et al.
Publicado: (2007)

Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica
por: Levy, Michael, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of esomeprazole and ranitidine during continuous venovenous hemodiafiltration
por: Fuhrmann, V, et al.
Publicado: (2013)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males
por: Okubo, Y, et al.
Publicado: (2011)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and piperaquine (PPQ)
por: Stein, Daniel S, et al.
Publicado: (2014)

Activated protein C–protein C inhibitor complex as a prognostic marker in sepsis
por: Heslet, Lars, et al.
Publicado: (2008)

Activated protein C–protein C inhibitor complex as a prognostic marker in sepsis
por: Heslet, L, et al.
Publicado: (2009)

Finding new potential acetylcholine esterase Inhibitors in SDFiles using CWM Lead Finder and PASS (Prediction of Activity Spectra for Substances)
por: Himmler, Hans-Jürgen, et al.
Publicado: (2008)

COMPLEMENT AS A MEDIATOR OF INFLAMMATION : ENHANCEMENT OF VASCULAR PERMEABILITY BY PURIFIED HUMAN C'1 ESTERASE
por: Ratnoff, Oscar D., et al.
Publicado: (1963)

Optimizing the dosing regimen of linezolid in critically ill septic patients undergoing continuous hemodiafiltration using a pharmacokinetic/pharmacodynamic analysis and monte carlo simulation
por: Barrasa González, H, et al.
Publicado: (2015)

Nebulized Cl-esterase inhibitor treatment does not attenuate pulmonary complement activation in a rat model of severe Streptococcus pneumoniae pneumonia
por: De Beer, FM, et al.
Publicado: (2014)

Serial change of C1 inhibitor in patients with sepsis: a preliminary report
por: Hirose, T, et al.
Publicado: (2015)

A systematic review of the efficacy and safety of a purified, pasteurized C1 inhibitor concentrate for the treatment of patients with type I or II hereditary angioedema
por: Bork, K, et al.
Publicado: (2010)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic variations during sepsis/septic shock
por: Bakdach, Dana
Publicado: (2019)

Activated protein C in sepsis: an Indian experience
por: Abraham, B, et al.
Publicado: (2005)

5613464 INTEGRATION OF PHARMACOKINETIC AND PHARMACODYNAMIC MODELS TO MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR PROSPECTIVE ASSESSMENT OF THE RISK-BENEFIT RATIO OF ORAL IRON CHELATORS IN PAEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT HAEMOGLOBINOPATHIES
por: Della Pasqua, O.D.P., et al.
Publicado: (2023)

Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Phenotypical analysis of peripheral human T lymphocytes in early sepsis
por: Nalos, M, et al.
Publicado: (2010)

Pharmacodynamic analysis and concentration mapping for efficient delivery through the FUS-induced BBB opening in non-human primates in vivo
por: Samiotaki, Gesthimani, et al.
Publicado: (2015)

Protein C in murine neonatal sepsis
por: Muchitsch, E, et al.
Publicado: (2005)

Controlled human malaria infections using aseptic, purified cryopreserved Plasmodium falciparum sporozoites administered by needle and syringe
por: Billingsley, Peter, et al.
Publicado: (2014)

Sepsis-induced lung fibrosis in baboons is reduced by the treatment with a complement inhibitor
por: Lupu, F, et al.
Publicado: (2011)

Risk/benefit analysis of activated protein C in patients with intra-abdominal sepsis
por: Borthwick, E, et al.
Publicado: (2007)

1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients
por: Katsube, Takayuki, et al.
Publicado: (2020)

Thrombin-activatable fibrinolysis inhibitor and organ dysfunction in disseminated intravascular coagulation associated with sepsis
por: Hayakawa, M, et al.
Publicado: (2011)

A sepsis progression model in humans: characterization of biomarkers descriptive of sepsis progression
por: Footer, BW, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3db73l8sg0giaabrdfn53n8msh